These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24671900)

  • 1. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up.
    Koziński M; Obońska K; Stankowska K; Navarese EP; Fabiszak T; Stolarek W; Kasprzak M; Siller-Matula JM; Rość D; Kubica J; De Servi S
    Cardiol J; 2014; 21(5):547-56. PubMed ID: 24671900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
    Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á
    Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
    Dridi NP; Johansson PI; Clemmensen P; Stissing T; Radu MD; Qayyum A; Pedersen F; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2014; 25(7):506-12. PubMed ID: 24245960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
    Lhermusier T; Lipinski MJ; Drenning D; Marso S; Chen F; Torguson R; Waksman R
    J Interv Cardiol; 2014 Aug; 27(4):365-72. PubMed ID: 25041356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
    Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M
    PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
    Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
    Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
    Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
    J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome.
    Furuse E; Takano H; Yamamoto T; Kubota Y; Yoshizane T; Kitamura M; Miyachi H; Hosokawa Y; Shimizu W
    Heart Vessels; 2017 Dec; 32(12):1432-1438. PubMed ID: 28685204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.